Original Publication Date: 1 February, 2017
Publication / Source: Future Oncology
Authors: Steven K Montalvo, Lianbo Li & Kenneth D Westover
RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies.